TPRKB: A Potential Drug Target and Biomarker for the Treatment of Parkinson's Disease

Target Name: TPRKB

NCBI ID: G51002

TPRKB

TPRKB: A Potential Drug Target and Biomarker for the Treatment of Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. It affects millions of people worldwide, primarily affecting older adults. The exact cause of Parkinson's disease is not known, but it is thought to involve the neurotransmitter dopamine, which is a critical molecule for the proper functioning of the brain. One of the primary targets for the treatment of Parkinson's disease is the protein TPRKB, which has been identified as a potential drug target and biomarker.

TPRKB: The Protein TPRKB

TPRKB stands for tyrosine-protein kinase B, and it is a protein that is expressed in various tissues throughout the body, including the brain. TPRKB is a member of the tyrosine-protein kinase family, which is a group of enzymes that regulate protein tyrosination, which is the process by which proteins are modified with tyrosine. The tyrosine-protein kinase family is important for the regulation of many cellular processes, including cell growth, differentiation, and survival.

TPRKB has been shown to play a role in the regulation of dopamine signaling in the brain. Dopamine is a neurotransmitter that is involved in the proper functioning of the brain, and it is thought to be involved in the development and progression of Parkinson's disease. TPRKB has been shown to regulate the tyrosination of dopamine receptors, which is the process by which dopamine binds to its receptors and transmits signals to the brain.

TPRKB and Parkinson's Disease

The tyrosination of dopamine receptors is thought to be involved in the development and progression of Parkinson's disease. Parkinson's disease is characterized by the progressive loss of dopamine-producing neurons in the brain, which leads to the loss of motor function. The exact mechanism by which the loss of dopamine-producing neurons leads to the development of Parkinson's disease is not known, but it is thought to involve the regulation of dopamine signaling by TPRKB.

TPRKB has been shown to play a role in the regulation of dopamine signaling in the brain by regulating the tyrosination of dopamine receptors. Studies have shown that TPRKB promotes the tyrosination of dopamine receptors and that the loss of TPRKB-expressing neurons is associated with the decreased tyrosination of dopamine receptors. This suggests that TPRKB may be a potential drug target for the treatment of Parkinson's disease.

TPRKB as a Biomarker

TPRKB has also been shown to be a potential biomarker for the diagnosis and progression of Parkinson's disease. The loss of TPRKB-expressing neurons is observed in the brains of individuals with Parkinson's disease, and this is associated with the decreased tyrosination of dopamine receptors. This suggests that TPRKB may be a potential biomarker for the diagnosis and progression of Parkinson's disease.

The decreased tyrosination of dopamine receptors is also observed in individuals with Parkinson's disease, which is associated with the loss of motor function. This suggests that TPRKB may be a potential drug target for the treatment of Parkinson's disease by increasing the tyrosination of dopamine receptors, which could potentially improve motor function.

Conclusion

TPRKB is a protein that has been shown to play a role in the regulation of dopamine signaling in the brain, and it is thought to be involved in the development and progression of Parkinson's disease. The loss of TPRKB-

Protein Name: TP53RK Binding Protein

Functions: Component of the EKC/KEOPS complex that is required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine (PubMed:22912744, PubMed:28805828). The complex is probably involved in the transfer of the threonylcarbamoyl moiety of threonylcarbamoyl-AMP (TC-AMP) to the N6 group of A37 (PubMed:22912744, PubMed:28805828). TPRKB acts as an allosteric effector that regulates the t(6)A activity of the complex. TPRKB is not required for tRNA modification (PubMed:22912744, PubMed:28805828)

The "TPRKB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPRKB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets